Are biosimilars really generics?

Expert Opinion on Biological Therapy

Volumn 10, Issue 4, 2010, Pages 489-494

  Misra, Anoop ^a,b,c  

^a FORTIS HOSPITAL   (India)

^b Obesity and Cholesterol Diseases Foundation N DOC   (India)

^c Diabetes Foundation India New Delhi   (India)

Author keywords

Biopharmaceuticals; Biosimilars; Generics; Manufacturing; Quality; Safety

Indexed keywords

ERYTHROPOIETIN; GENERIC DRUG; GRANULOCYTE COLONY STIMULATING FACTOR; HUMAN GROWTH HORMONE; INSULIN; RECOMBINANT ERYTHROPOIETIN;

BIOLOGICAL ACTIVITY; DRUG EFFICACY; DRUG FORMULATION; DRUG ISOLATION; DRUG LEGISLATION; DRUG MANUFACTURE; DRUG MARKETING; DRUG PURIFICATION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; HUMAN; INDIA; REVIEW;

BIOLOGICAL PRODUCTS; DRUG INDUSTRY; DRUGS, GENERIC;

EID: 77949469515     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712591003662615     Document Type: Review

References (37)

1. Roger SD. Biosimilars: how similar or dissimilar are they? Nephrology 2006;11:341-346
2. Pisani J, Bonduelle Y. Opportunities and barriers in the biosimilar market: Evolution or revolution for generics companies? Bangalore, India: Association of Biotechnology Led Enterprises (ABLE) Available from: http://www.ableindia.org/biosimilars.pdf [Last accessed 30 January 2010]
3. Ronco C. Is the advent of biosimilars affecting the practice of nephrology and the safety of patients? Contrib Nephrol 2008;161:261-270
4. Schellekens H. Biopharmaceuticals and biosimilars, unraveling the complexity. EJHP Pract 2006;5:13
5. Nowicki M. Basic facts about biosimilars. Kidney Blood Press Res 2007;30:267-272
6. Mikhail A. Biosimilars in clinical practice. Kidney Blood Press Res 2007;30(Suppl 1):18-22
7. Bohlega S, Al-Shammri A, Al Sharoqi I, et al. Biosimilars: opinion of an expert panel in the Middle East. Curr Med Res Opin 2008;24(10):2897-2903
8. Frequently asked questions about generic medicines. Brussels, Belgium: European Generic Medicines Association, 2007. Available from: www.egagenerics.com/ FAQ-generics.htm [Last accessed 30 January 2010]
9. Questions and answers on generic medicines. EMEA document. EMEA/ 393905/2006. London, UK: European Medicines Agency, 2007. Available from: www.emea.europa.eu/pdfs/human/pcwp/ 39390506en.pdf [Last accessed 30 January 2010]
10. Questions and answers on biosimilar medicines (similar biological medicinal products). EMEA document EMEA/ 74562/2006. London, UK: European Medicines Agency, 2007. Available from: www.emea.europa.eu/pdfs/human/pcwp/ 7456206en.pdf [Last accessed 30 January 2010]
11. Locatelli F, Roger S. Comparative testing and pharmacovigilance of biosimilars. Nephrol Dial Transplant 2006;21(Suppl 5):v13-16
12. EBE-EFPIA Position Paper. Inapplicability of automatic substitution rules to biotechnology products, including biosimilar medicinal products: Recommendations for addressing unique safety concerns. Available from: http://www.ebe-biopharma.org/ documents/biosimilars/ biosimilars- substitutionpos.pdf [Last Accessed 10 December 2009]
13. Casadevall N, Rossert J. Importance of biologic follow-ons: experience with EPO. Best Pract Res Clin Haematol 2005;18:381-387
14. Lim LC. Acquired red cell aplasia in association with the use of recombinant erythropoietin in chronic renal failure. Hematology 2005;10:255-259
15. Schellekens H. Follow-on biologics: challenges of the 'next generation'. Nephrol Dial Transplant 2005;20(Suppl 4):iv31-36
16. Declerck PJ. Biotherapeutics in the era of biosimilars: what really matters is patient safety. Drug Saf 2007;30(12):1087-1092
17. Kuhlmann M, Covic A. The protein science of biosimilars. Nephrol Dial Transplant 2006;21(Suppl 5):v5-8
18. Schellekens H. Bioequivalence and the immunogenicity of biopharmaceuticals. Nat Rev Drug Discov 2002;1:457-462
19. Chirino AJ, Mire-Sluis A. Characterizing biological products and assessing comparability following manufacturing changes. Nat Biotechnol 2004;22:1383-1391
20. Crommelin DJ, Storm G, Verrijk R, et al. Shifting paradigms: biopharmaceuticals versus low molecular weight drugs. Int J Pharm 2003;266:3-16
21. Wenzel RG. Biosimilars: illustration of scientific issues in two examples. Am J Health Syst Pharm 2008;65(14 Suppl 6):S9-15
22. Robertson JS. Changes in biological source material. Biologicals 2006;34:61-63
23. Schellekens H. Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin Ther 2002;24:1720-1740
24. Belsey MJ, Harris LM, Das RR, et al. Biosimilars: initial excitement gives way to reality. Nat Rev 2006;5:535-536
25. Roger SD, Mikhail A. Biosimilars: opportunity or cause for concern? J Pharm Pharm Sci 2007;10(3):405-410
26. Schellekens H. When biotech proteins go off-patent. Trends Biotechnol 2004;22(8):406-410
27. Kessler M, Goldsmith D, Schellekens H. Immunogenicity of biopharmaceuticals. Nephrol Dial Transplant 2006;21(Suppl 5):v9-12
28. Schellekens H, Casadevall N. Immunogenicity of recombinant human proteins: causes and consequences. J Neurol 2004;251(Suppl 2):II4-9
29. Chirino AJ, Ary ML, Marshall SA. Minimizing the immunogenicity of protein therapeutics. Drug Discov Today 2004;9:82-90
30. Schellekens H. How similar do"biosimilars" need to be? Nat Biotech 2004;22(11):1357-1359
31. Guideline on similar biological medicinal products. London, UK: European Medicines Agency, 2005. Available from: http://www.ema.europa.eu/pdfs/human/ biosimilar/043704en.pdf [Last Accessed 30 January 2010]
32. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues. London, UK: European Medicines Agency, 2006. Available from: http://www.ema.europa. eu/pdfs/human/biosimilar/4934805en.pdf [Last accessed 30 January 2010]
33. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. London, UK: European Medicines Agency, 2006. Available from: http://www.ema.europa.eu/pdfs/human/ biosimilar/4283205en.pdf [Last accessed 30 January 2010]
34. Mellstedt H, Niederwieser D, Ludwig H. The challenge of biosimilars. Ann Oncol 2008;19:411-419
35. Joshi SR. Biosimilar Insulins: are they really 'similar'? JAPI 2009;57(Suppl):338-341
36. Joung J, Robertson JS, Griffiths E, et al. WHO informal consultation on regulatory evaluation of therapeutic biological medicinal products held at WHO Headquarters, Geneva, 19-20 April 2007. Biologicals 2008;36:269-276
37. Central Drug Standards Control Organization. Biological Guidance for Industry. New Delhi, India: Central Drug Standards Control Organization, Ministry of Health& Family Welfare, Government of India. 2009. Available from: http://cdsco.nic.in/ CDSCO-GuidanceForIndustry.pdf [Last accessed 30 January 2010